IRWIN NATURALS SUB VTS - IWINF STOCK NEWS

Irwin Naturals has announced a proposed acquisition of Braxia Scientific Corp, a medical research firm specializing in innovative ketamine treatments, via a non-binding Letter of Intent. The acquisition is valued at US$30 million, with a significant premium of approximately 315.72% over Braxia's share price. This strategic move is expected to enhance Irwin's footprint with 17 specialized mental health clinics across North America, further enriched by a telehealth platform. The completion is contingent upon due diligence, corporate approvals, and regulatory consents, among other conditions. This combination aims to create a market leader in mental health services.

Irwin Naturals has announced a licensing agreement with C3E Management, LLC to produce and distribute THC products in Oklahoma, a significant step in expanding its cannabis offerings across legalized states. The partnership aims to enhance product availability in approximately 2,700 dispensaries in Oklahoma. Irwin Naturals, a recognized brand in herbal supplements since 1994, is positioning itself as a leading name in the THC market. This aligns with the company's strategy to leverage its brand trust as it seeks to enter the cannabis and psychedelics sectors, following prior agreements in California, Colorado, Ohio, and New Mexico.

Irwin Naturals (CSE: IWIN, OTC: IWINF) has entered into a Letter of Intent with Braxia Scientific Corp. to collaborate on Clinical Research Services across its US network of Emergence clinics. The partnership aims to enhance mental health treatments and will involve an investment of up to $2 million over the next year, starting with five clinics in Florida. Braxia brings its expertise in innovative therapies to support multiple pharmaceutical and biotechnology sponsors. This partnership is subject to final legal agreements and is poised to advance Irwin’s clinical research capabilities.

Irwin Naturals (CSE: IWIN) (OTC: IWINF) has entered into a licensing agreement with Hyphae Wellness, an Oregon cannabis product developer, to manufacture and distribute its THC products in Oregon. CEO Klee Irwin emphasized the importance of Oregon as a key market and praised Hyphae for its quality. This agreement extends Irwin's distribution to five of the 19 states where recreational cannabis is legal, including major markets. Additionally, the company issued 20,000 warrants at US$3.00 each to conserve cash resources. Irwin Naturals is recognized in 80% of American households.

Irwin Naturals Inc. (CSE: IWIN) reported its Q3 2022 results, showing a 7% decline in total operating revenue, attributed mainly to CBD supply issues. However, gross margins improved by 4.8% year-over-year, driven by a favorable sales mix and successful price increases. The company has expanded aggressively in the mental health clinic sector, acquiring 18 clinics to date and entering licensing deals in six states and Canada. Despite operational challenges, net loss has decreased by 60.2% compared to Q3 2021, and the financial outlook remains strong with significant working capital available.

Irwin Naturals Inc. has acquired the assets of Tri-Cities Infusion & Wellness Clinic in Kennewick, Washington, marking the addition of its 17th facility in a rapidly expanding network for psychedelic mental healthcare. The acquisition, signed on November 5, 2022, allows the company to enhance its Irwin Naturals Emergence chain of clinics specializing in ketamine treatment and other mental health therapies. This strategic move is part of Irwin's broader expansion into the psychedelic sector and aims to provide improved mental health services across the U.S.

Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) has announced a licensing agreement with Mockingbird Cannabis to launch THC products in Mississippi. The deal positions Irwin as a key player in the medical marijuana market, utilizing Mockingbird's established infrastructure and market presence. The Mississippi medical marijuana market has recently been legalized, with over 100 dispensaries expected to operate soon. Irwin Naturals aims to leverage its strong brand recognition, reaching 80% of American households, and expand its THC product line across states where legality permits.

Irwin Naturals announced its acquisition of the Clare Clinic, expanding its network of mental-healthcare clinics in Florida. The deal, finalized on October 30, 2022, adds three clinics in Gainesville, Tallahassee, and Panama City to its existing five locations. The company aims to lead in psychedelic mental healthcare, leveraging its established brand and operational efficiencies. The transaction involves a mix of cash and stock, contingent on performance milestones, and follows an automatic share purchase plan to support its Normal Course Issuer Bid.

Irwin Naturals has announced the acquisition of Dura Medical in Naples, Florida, enhancing its national network of psychedelic mental healthcare clinics. This acquisition is part of the company's strategy to build the largest chain of such clinics in the U.S., focusing on ketamine-infusion therapy. The clinic will join the existing five locations in Florida under the Irwin Naturals Emergence brand. The transaction involves a mix of cash and stock, aligning seller interests with shareholders. The company also announced a transition in its CFO role as part of its ongoing operational developments.